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ABSTRACT
Background The diagnosis of lower urinary tract 
symptoms related to suspected bladder outflow 
obstruction from benign prostate hyperplasia/enlargement 
in men is increasing. This is leading to high demand on 
healthcare services; however, there is limited knowledge 
of differences in pharmacotherapy prescribing for this 
condition based on geography.
Objective To investigate potential variation in drug 
prescribing for suspected bladder outflow obstruction in 
Scotland, based on analysis of publicly available data, to 
identify trends and inform future prescribing.
Study design A longitudinal register- based data study 
of prescribing and patient data publicly available from 
Scottish registries. All information is available as monthly 
aggregates at the level of single general practices.
Setting and participants 903 (97%) general practices 
in Scotland, over a 50- month period (October 2015 to 
November 2019).
Outcome measurements and statistical analysis We 
analysed numbers of daily doses of drugs for suspected 
bladder outflow obstruction prescribed per month using 
a Bayesian Poisson regression analysis, incorporating 
random effects to account for spatial and temporal 
elements.
Results Prescriptions for suspected bladder outflow 
obstruction medications increased during the observation 
period (overall average rate of change 1.24±0.28, ranging 
from 0.893 in Orkney to 1.95 in Lanarkshire). While some 
determinants of health inequality regarding prescribing 
practices across health boards are consistent with those 
known from the literature, other inequalities remain 
unexplained after accounting for practice- specific and 
patient- specific characteristics such as deprivation and 
rurality.
Conclusions Inequalities in prescribing for suspected 
bladder outflow obstruction medications exist in Scotland, 
partially ascribable to accepted sociodemographic and 
geographic factors.
INTRODUCTION
The incidence of bothersome lower urinary 
tract symptoms (LUTS) in men, which are 
predominantly attributable to benign pros-
tate hyperplasia (BPH) and/or benign 
prostatic enlargement causing proven or 
suspected bladder outflow obstruction 
(BOO), is increasing globally, resulting in 
reduced quality of life and increased health-
care expenditure.1 2 In Scotland, men with 
suspected or proven BOO are generally 
managed in primary care with medication 
prescribed by general practitioners (GPs) 
and/or specialist practitioners, with such 
medication either prescribed by GPs alone 
or as part of shared care with specialists such 
as urologists.1 Scottish healthcare services, 
that treat men with prostate conditions face 
increased demand resulting from an ageing 
population, increased prostate cancer (PCa) 
investigation3 4 and increased awareness of 
men’s health issues, which is likely to have 
Strengths and limitations of this study
 ► This is the first study to investigate spatial and 
temporal variations in drug- prescribing patterns 
for bladder outflow obstruction using geostatistical 
models.
 ► As such, this data provide a new perspective to in-
form clinical practice.
 ► The statistical framework described in this paper is 
very general and can be readily extended to other 
settings and conditions.
 ► Data on drug prescribing in Scotland only exist in the 
public domain at an aggregate (ie, individual gener-
al practitioners’ practice or patient list) level, which 
limits the granularity of the analysis.
 ► The use of summary data regarding levels of socio-
economic deprivation and rurality of patients reduc-
es the accuracy with which one can estimate the 
shape of their association with the outcome. These 
factors are likely to be important in terms of access 
to healthcare and prescribing.
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impacted on the care of men with bothersome LUTS 
arising from BOO. Studies reporting the incidence and 
prevalence of LUTS in men are predominantly cross- 
sectional in nature, with widely varying results.5
Scotland’s diverse geography provides an ideal land-
scape to understand how factors that may impact on 
prescribing patterns may differ spatially in terms of geog-
raphy and longitudinally.6 Prescribing trends in Scotland 
vary geographically by urban/rural and sociodemo-
graphic classifications6 and by unique regional cultures 
or as a result of strong ‘social patterning’, one example 
being the so- called ‘Glasgow effect’.7 8 Furthermore, it 
has been acknowledged that aspects regarding individual 
GP medical practices may contribute to prostate health 
inequalities across UK.9 10
Data regarding the prescription of drugs for the medical 
management of BOO as a cause for male bothersome 
LUTS have been used internationally in recent years to 
increase the understanding of patterns of prescribing 
within specific populations. This approach can be useful 
to identify potential demographic inequalities in patient 
access to healthcare for this condition and to understand 
the patient experience, predominantly using longitudinal 
data sets.11–13 However, to date, there is limited knowl-
edge of how the prescribing patterns for drugs used to 
treat BOO may differ both spatially and temporally. The 
increasing availability of high- quality open access health-
care data in Scotland has created the opportunity for a 
more refined and broader- based analysis of prescribing 
patterns for BOO.
We investigated the possibility that differences may 
exist in Scotland in the prescribing patterns of the two 
main classes of medications used to treat bothersome 
LUTS secondary to BOO. We performed an analysis of 
publicly available data in order to identify possible vari-




Data were acquired and linked from numerous inde-
pendent and publicly accessible sources. The data set 
comprised information at the level of individual general 
practices and was created from the following four sources:
1. National Health Service (NHS) Scotland OpenData: 
drug prescriptions monthly data (https://www. openda-
ta. nhs. scot/ dataset/ prescriptions- in- the- community).
2. Information Services Division Scotland (ISD): practice 
details, deprivation, rurality (https://www. isdscotland. 
org/ Health- Topics/ General- Practice/).
3. National Institute for Health and Care Excellence 
(NICE): daily dosages (https://www. nice. org. uk).
4. National Records of Scotland (NRS): postcodes, health 
boards (https://www. nrscotland. gov. uk/ statistics- and- 
data/ geography/ our- products/ scottish- postcode- di-
rectory/ 2018- 2).
The keys used to link the sources were the unique 
GP practice code and date. The ISD and NRS portals 
provided information regarding both the medical prac-
tice and their patient population. Table 1 contains a list 
of variables extracted from these sources. We used both 
deprivation and rurality to account for sociodemographic 
status. In particular, we used the 2016 Scottish Index of 
Multiple Deprivation14 and a recoded version of the 2018 
Scottish Government Urban Rural Classification.15 In 
addition, the ISD and NRS sources provided GP practice- 
level information regarding the size of the individual 
practice patient list, the gender and age distribution and 
the location of the practice (based on postcode and name 
of relevant Health Board). All GP practices open for the 
whole study period (October 2015 to November 2019) 
were included in the data set (903 of 944, 95.7%, prac-
tices in Scotland open as of 1 January 2019). The Scottish 
Open Data portal provided the prescribed amounts of 
the drugs of interest per month.
BOO medications analysed
We specifically focused on the prescribing of α−1 blocking 
drugs and 5-α reductase inhibitors as these are the only 
Table 1 Variables extracted from the four data sources and 
used as covariates in the statistical model
Variable Type Short description













  Is the practice run by GPs 
(contract type 17J and 17C), 
rather than by the NHS 






  Does the GP practice 
have a license to dispense 
medicines? Yes/no
Men 45+ Numerical, 
time- varying
Proportion of patients that are 





  Proportion of patients under 




  Modal rurality index among 
the patients (Scottish 
Government 8- fold Urban 
Rural Classification) recoded 
as remote (4, 5, 7, 8) or non- 
remote (1, 2, 3, 6). Yes/no
Postcode Categorical, 
baseline






  Name of Scottish Health 
Board where the GP practice 
is situated.
GP, general practitioner; NHS, National Health Service; SIMD, 
Scottish Index of Multiple Deprivation.
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specific medications used for BOO. α−1 blockers are the 
firstline and most commonly used drugs prescribed for 
LUTS secondary to BOO,1 16 while 5-α reductase inhibi-
tors are generally recommended where men are consid-
ered at high risk of BPH progression due to a significantly 
enlarged prostate, either as monotherapy or in combina-
tion with α−1 blockers.1 16 17 The α−1 blockers alfuzosin 
and tamsulosin hydrochloride were included in the study; 
however, doxazosin and terazosin were not included as 
the amounts of these drugs prescribed were negligible, 
while doxazosin may be prescribed for hypertension. 
The 5-α reductase inhibitors, dutasteride and finas-
teride, were both included in this study. When combined 
with the suggested daily dosages from the NICE website 
(see table 2), a proxy for the number of daily doses 
was constructed by rounding to the nearest integer the 
following expression:
 ndti =
#tablets of drug d prescribed during month t at practice i
daily suggested dosage for drug j # (1)
where i, d, and t represent the GP practice, drug and 
month, respectively. In our data set, we have obser-
vations for i=1,…,903 GP practices over t=1,…,50 
months; d indexes the drugs reported in table 2. The 
number of daily doses for each of the drug groups 
was then constructed by summation of the respective 
drugs’ monthly amounts of daily doses. We denote with 
njti the number of daily doses of drugs belonging to 
group  j ∈
{
α1 − blocker, 5 − α reductase inhibitor
}
 , 
prescribed during month t, at each GP practice i.
We then used a Poisson model in order to describe 
the average number of daily doses of BOO medication 
prescribed each month, accounting for each of the 
covariates presented in table 1, with additional spatial 
and temporal random effects. Possible interactions 
between individual GP practices' prescribing patterns, or 
geographical location, with the prescribed drug type were 
also investigated.
Equation 1 describes the model’s functional form, 
while table 3 summarises our choices in terms of spatial 
and temporal structure. Further details of the statistical 
analysis are provided as supplementary material.










+β2drug group + β3contracti + β4dispensingi
+β5males 45pti + β6deprived 15ti + β7remoteti# 
(2)
where j (drug group), t (month) and i (each GP prac-
tice) are as described, and  α
[
i
],α[ji],α[tji]  denote the 
random effects, summarised in table 3. A detailed discus-
sion of the choice of the random components of the 
model is available in online supplemental file 1).
Computational analysis
All computational analyses were carried out in R 3.6.1.18 
We estimated the model parameters within the Integrated 
Nested Laplace Approximation framework using the inla 
package.19 The code is available as online supplemental 
file 2, while data and shapefiles are from an external 
repository.20
RESULTS
We investigated the effects of each of the available covari-
ates (including GP practice patient list size; BOO drug 
group; whether the practice was GP run; whether the GP 
practice dispensed medication; proportion of men aged 
45 years; higher proportion of socioeconomic depriva-
tion and remote/rural location) on the study outcome. 
Table 4 contains summary statistics on the sample.
Table 5 summarises the output of the Poisson regres-
sion estimates of each of the associated parameters. In a 
further analysis, we interpreted each of these parameters 
in terms of relative differences from the model average 
(with the exception of GP practice list size).
The GP practice patient list size was observed to have 
an effect consistent with an estimated increase of slightly 
less than one daily dose per month per additional patient 
(point estimate 0.915). As expected, the prescribed 
doses of the  5 − α reductase inhibitor drug group were 
observed to be on average less than the prescribed 
doses of the  α− 1 blocker drug  group. The estimated 
relative difference was calculated to be on average 
45%–48% fewer  5 − α reductase inhibitor drug prescrip-
tions than  α− 1 blocker drug prescriptions per month 
(point estimate 46%).
Table 2 Suggested daily dosages of the study α−1 





Alfuzosin α−1 blocker 2.5 mg three times 
a day
10 mg once daily
Tamsulosin cap/tab α−1 blocker 400 mcg once daily
Dutasteride 5-α reductase 
inhibitor
500 mcg once daily
Finasteride 5-α reductase 
inhibitor
5 mg once daily
NICE, National Institute for Health and Care Excellence.
Table 3 Spatial and temporal random effects
Parameter Type Short description
α[i] Spatial Intrinsic conditional auto- 
regressive
α[Ii] Unstructured Unstructured interaction 
between GP practice and drug 
type
α[tji] Temporal First- order auto- regressive, 
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We observed that the nature of how the GP prac-
tices are individually run is associated with BOO drug 
prescribing practice, with GP- run practices (rather than 
by direct NHS- run practices) having larger volumes of 
these prescriptions. The model results are consistent 
with 19%–35% (point estimate 27%) increased number 
of monthly prescriptions for GP- run practices compared 
with NHS- run practices, all else being equal. This is an 
interesting result, and to the best of our knowledge, no 
rigorous research has been undertaken to investigate 
the role that how a GP practice is managed plays on 
the stability of provision of care and, in turn, on help- 
seeking behaviours and clinical outcomes. Conversely, 
we observed that GP- dispensing practices are associated 
with 3%–13% (point estimate 8%) lower volumes of BOO 
drug prescriptions compared with GP practices without 
a pharmacy, keeping all other variables constant. Prac-
tices that dispense usually tend to do so because there 
is no local community pharmacy, and they need one to 
fit a need; one way of thinking about this is that having 
a dispensing licence may reflect an aspect of remoteness 
that is not captured by the rurality measure we employ. 


















53 3091 (2563) 1320 (1192) 6625 (4831) 1.00 0.06 0.25 (0.03) 0.20 (0.24) 0.18
Borders 23 2054 (1838) 1374 (983) 4862 (3343) 1.00 0.17 0.26 (0.01) 0.00 (0.09) 0.13
Dumfries and G. 31 2231 (1449) 966 (782) 3976 (3492) 1.00 0.39 0.27 (0.04) 0.00 (0.08) 0.20
Fife 53 2699 (1805) 1372 (820) 6367 (4313) 0.96 0.02 0.23 (0.03) 0.13 (0.23) 0.04
Forth Valley 51 2144 (1767) 1515 (1260) 5844 (4606) 0.94 0.02 0.23 (0.02) 0.06 (0.16) 0.13
G.Glasgow and 
Clyde
230 1658 (1692) 826 (924) 4863 (3620) 1.00 0.01 0.21 (0.04) 0.33 (0.43) 0.04
Grampian 70 3204 (2595) 1462 (1228) 7980 (4875) 0.94 0.17 0.24 (0.04) 0.00 (0.02) 0.28
Highland 95 1002 (1486) 504 (810) 2358 (4467) 0.85 0.39 0.27 (0.05) 0.00 (0.05) 0.56
Lanarkshire 97 1665 (2161) 1428 (1406) 6048 (4570) 0.99 0.02 0.22 (0.02) 0.23 (0.22) 0.10
Lothian 112 2205 (1700) 1176 (1008) 7814 (4229) 0.95 0.00 0.21 (0.04) 0.02 (0.12) 0.03
Orkney 6 1675 (1217) 1008 (929) 2908 (2379) 0.83 0.33 0.28 (0.03) 0.00 (-) 0.70
Shetland 10 690 (1107) 253 (560) 1143 (1913) 0.20 0.70 0.24 (0.04) 0.00 (-) 0.92
Tayside 63 3103 (2140) 1645 (1166) 6685 (4676) 0.94 0.02 0.23 (0.05) 0.05 (0.24) 0.12
Western I. 9 892 (1891) 588 (665) 1389 (4046) 1.00 0.89 0.30 (0.06) 0.00 (-) 0.76
Number of practices, median and (IQR) for continuous variable, proportions for categorical variables. Counts are rounded to the nearest 
integer, proportions to the second decimal place.
GP, general practitioner.
Table 5 Summary of estimated posterior distributions for the fixed effects, containing the model estimates with associated 
uncertainty, on the rate ratio scale
Mean SD 2.5% 50% 97.5% Mode
α—iIntercept 0.208 0.008 0.192 0.208 0.225 0.208
β1—log(GP practice patient list size) 0.915 0.002 0.911 0.915 0.919 0.915
β2—drug group (5-α reductase inhibitors) 0.536 0.009 0.518 0.535 0.554 0.536
β3—GP run practices 1.269 0.042 1.190 1.268 1.352 1.269
β4—dispensing GP practice 0.918 0.024 0.871 0.917 0.966 0.918
β5—Men aged ≥45 years 1.049 <0.001 1.049 1.049 1.050 1.049
β6—socially deprived area 1.017 0.007 1.003 1.017 1.031 1.017
β7 —remote/rural GP practice 1.002 <0.001 1.002 1.002 1.003 1.002
The posterior distribution associated to the patient list size effect estimate β1 was not transformed and should be read on the outcome scale, 
as explained in- text.
GP, general practitioner.
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We found the proportion of men aged ≥45 years in the 
GP practice patient list to be positively associated with the 
volume of BOO prescriptions, with an estimated average 
increase in the monthly rate of prescription of 4.9% per 
percentage point. In contrast, the levels of deprivation, 
and a remote/rural geographical location of each GP 
practice, were found to have a negligible association with 
prescribing practice.
Next, we investigated the statistical model’s interpola-
tions according to Health Board and drug group (α−1 
blocking drugs and 5-α reductase inhibitors) (figure 1). 
This analysis highlighted a general increase in the 
volumes of prescriptions for these medications over the 
4- year study period. Trends in prescribing were observed 
to be broadly similar across most Health Boards, with a less 
prominent increase in less populated areas, which may 
potentially be attributable to a more stable population 
structure over the 4- year period of observation as well as 
unaccounted for differences in help- seeking behaviours. 
Within most Health Boards, the growth in prescriptions 
for each drug group was almost parallel during the 4- year 
observation period, suggesting consistency in terms of 
increased BOO drug prescribing. Additional observa-
tions included a marked shift in volumes of α−1 blocking 
drug prescriptions in Lanarkshire between November 
2016 and February 2017; however, no further specific 
information regarding this phenomenon was available 
within the publicly available data set. In the absence of 
a reasonable explanation for this singular observation in 
this one Health Board, this has been treated as an artefact 
due to a change in data- recording criteria.
Next, we investigated how the statistical model resid-
uals may provide insight into how BOO drug prescribing 
behaviour differed across Scotland during the 4- year 
study period. Figure 2 illustrates histograms of exponen-
tiated residuals for each individual Health Board across 
Scotland, where a reference value of  1 = e0 represents a 
null residual (ie, there is no deviation from the model’s 
predicted average). Each residual is specific to one indi-
vidual anonymous GP practice. On an exponential scale, 
a value of 1 indicates a prescribing behaviour in line 
with the average as described by the statistical model 
across Scotland during the study period. A value below 
1 indicates prescribing volumes higher than expected 
based on the model, while a value larger than 1 indi-
cates prescribing volumes lower than expected. Asym-
metry around the reference value of 1, and/or multiple 
modes of distribution, suggests a different behaviour of 
individual GP practices within a Health Board compared 
against the national average across Scotland.
Using this statistical approach, we generally observed 
consistency in the prescription of drugs for BOO across 
Health Boards in Scotland, with most distributions 
appearing to be approximately unimodal and symmetric 
around the null residual (ie, the reference value of  1 = e0
 ). However, some interesting patterns of prescribing can 
be observed, such as the reduced level of BOO drug 
prescribing in some individual Health Boards (most 
Figure 1 Statistical model average number of daily doses of each BOO drug type prescribed per month, by individual Scottish 
Health Board and adjusted for GP practice patient roll size. BOO, bladder outflow obstruction; GP,general practitioner.
 on F
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notably Borders, Forth Valley, Tayside, Orkney and Shet-
land) compared with the average prescribing rate across 
Scotland. The reasons for these differences in prescribing 
pattern in these individual Health Boards are unclear and 
require further investigation.
Next, we examined the BOO drug- prescribing patterns 
of GP practices with the aim of assessing and visualising 
possible spatial patterns. Once again using the model 
residuals, it was possible to identify individual anonymous 
practices at the extremes of the BOO prescribing distribu-
tion and show their Health Board location on a map. This 
approach can be useful in order to detect geographic clus-
ters of similar prescribing patterns, while accounting for 
temporal trends and other potential confounding factors 
that are already included in the model. For example, the 
policymaker might be interested in identifying clusters of 
GP practices where the rates of prescribing are either very 
low or very high with respect to the national average. We 
present the results of such analysis in figure 3 where, to 
preserve anonymity of the individual practices, we have 
aggregated the information at the Health Board level. We 
denote those GP practices with a model residual below 
the 2.5% percentile of the overall distribution of residuals 
as ‘high- volume prescribers’ and those above the 97.5% 
percentile as ‘low- volume prescribers’. We stress that 
high- volume and low- volume are with respect to the 
national average as described by the model. Moreover, 
the quantile thresholds are arbitrary and can be adjusted 
according to the analytical need.
We observed that Highland is the Health Board with 
the largest percentage (~9.5%) of GP practices that 
were identified as being in the upper tail of prescribing 
volumes (identified by model residuals <2.5% percentile), 
followed by Lothian (~5.3%), Dumfries and Galloway 
(~3.2%), Grampian (~2.9%), Forth Valley (~2%) and 
Greater Glasgow and Clyde (~1.7%). No ‘high- volume 
prescriber’ GP practices were found within the remaining 
Health Boards. On the other hand, Tayside was identified 
as the Health Board with the largest percentage (~19%) 
of ‘low- volume prescribers’ (identified by model residuals 
>97.5% percentile). Shetland (10%), Borders (~8.7%), 
Grampian (~5.7%), Highland (~1.1%), Lothian (~1%) 
and Greater Glasgow and Clyde (~0.9%) also contained 
GP practices that prescribed far below the national 
average. The remaining Health Boards did not contain 
any ‘low- volume prescribing’ practices. The underlying 
Figure 2 Frequency histograms of the statistical model’s exponentiated residuals for each Scottish Health Board. The 
vertical dashed line represents the null residual (value=1 on the exponentiated scale), and each small black square represents 
the average number of daily prescriptions of BOO drugs (combined α−1blockers and 5-α reductase inhibitors) per month 
per individual anonymous GP practice within each Health Board. The boxplot below each histogram illustrates the same 
data distribution (the white point marks the median, the thick line represents the usual box and the thin line represents the 
whiskers). Ideally the exponentiated residuals for each GP practice would lie around the null residual (ie, value=1); however, 
the heterogeneity in prescribing practice is illustrated by increased spread to the left and right of the null residual. A shift of 
GP practice distributions to the right of the null residual, as seen in Health Boards such as Borders, Fife, Orkney, Shetland and 
Tayside, illustrates less prescribing of these medications than would be expected. BOO, bladder outflow obstruction; GP,general 
practitioner.
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reasons for these observations are currently unclear and 
require further investigation.
DISCUSSION
This study has investigated possible differences in patterns 
of medical prescribing for the two most common classes 
of drugs (ie,  α− 1 blockers and  5 − α reductase inhibi-
tors) used to treat BOO in Scotland over a recent 4- year 
period (October 2015–November 2019) using publicly 
available data from individual GP practices across all 
Health Boards. In taking this approach, we have assumed 
that most BOO medication is prescribed by GPs, either 
practising alone or on the advice of a specialist prescriber 
such as a urologist from specialist practice, as is the case 
throughout the UK. Nevertheless, using this approach 
and GP practice prescribing data with this assumption, 
we generated a study data set by linking prescribing data 
to GP practice- specific information (such as their type 
of contract with the NHS and their licence to dispense) 
and summary characteristics of their patient populations 
(such as patient age and GP practice- associated levels of 
deprivation and rurality). To our knowledge, this is the 
first time that particular characteristics of a GP practice 
have been studied as potential factors influencing BOO 
drug prescribing patterns in Scotland. This has enabled 
us to identify trends in prescribing behaviour that may 
help inform future practice.
A trend of increased BOO drug prescribing practice 
was observed throughout the 4- year observation window 
consistent with trends in increased detection of PCa 
(which is prevalent in men of the same age), an ageing 
Scottish population, increased awareness of male health 
issues among both patients and GPs and increased 
referral of men to secondary care due to a raised PSA.21 22 
Though gaining a definite understanding of this trend 
was outside the scope of this study, in order to fully under-
stand the nature of this increase, it would be pertinent to 
(1) identify the relative contribution (or otherwise) made 
by increased referral to secondary care with suspected 
PCa (as identified by a raised PSA), which might result in 
increased BOO/BPH prescribing as a secondary conse-
quence of a raised PSA referral, (2) the currently unac-
counted for impact of increased GP and public awareness 
and public help seeking behaviour and (3) increased 
focus on PCa management, rather than BPH surgery, 
which may have contributed to the increase in medical 
drug use for BOO, rather than definitive intervention, 
though this is speculative. Greater understanding of these 
issues will facilitate planning to meet demand in primary 
care services given ongoing capacity shortage, and also 
secondary care as increased pharmacological treatment 
could be indicative of future demand for surgery.23
Whether practices were NHS or GP- run, or had a 
dispensing pharmacy present within the GP practice, 
were associated with higher and lower prescribing 
volumes, respectively. While the individual characteristics 
of GP medical practices are known to differ by region24 
research accounting for these factors is relatively sparse; 
hence, it is unclear why this difference exists. Further-
more, although regional prescribing behaviours were 
largely uniform, lower levels of prescribing were noted 
in some individual Health Boards. No clear explana-
tion could be given for this observation, as no possible 
explanatory factor is common to these Health Boards. An 
Figure 3 Maps of Scotland highlighting the Health Board locations of anonymous GP practices at the extremes of the 
distribution of BOO drug prescribing. The left panel shows the percentage of GP practices within each Health Board that 
have been identified (via model residuals) as being high in prescribing volumes with respect to the national average (ie, model 
residuals <2.5% percentile). Similarly, the right panel shows the percentage of GP practices low in prescribing volumes 
with respect to the national average (ie, model residuals >97.5% percentile). BOO, bladder outflow obstruction; GP, general 
practitioner.
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investigation of factors listed above would be pertinent 
to understand regional differences evident in prescribing 
behaviours and guide intervention to reduce inequity.
This study found several GP practices operating at 
the extremes of prescribing, with practices across five 
Health Boards prescribing considerably more, and prac-
tices across seven Health Boards prescribing consider-
ably less, of each drug than other Scottish practices. In 
particular, 19% of GP practices in Tayside were consid-
ered to be ‘low- volume prescribers’, which could partially 
explain why Tayside was found to have lower overall 
levels of prescribing. However, there was otherwise no 
correlation between individual GP practice prescribing 
behaviours and overall volume of prescriptions within 
the Health Board. As such, this study found that factors 
other than GP list size or accepted sociodemographic and 
geographic measures may be contributing to inequalities 
in prescribing practice. Further research is needed to 
identify these factors, although individual GP attitudes 
and understanding of prostate diseases,9 10 and Scotland’s 
cultural diversity,7 8 18 may be potential explanations.
The data used in this research had several limitations. 
First, the available data only exist in the public domain at 
an aggregate level (ie, individual GP practice or patient 
list), and further information would be helpful in order 
to identify the reasons why prescribing practices vary 
at a more granular level (perhaps by associating the 
prescribing practice with the presence or absence of a 
GP with a particular interest in men’s health issues, as an 
example). Second, the use of summary data regarding 
levels of socioeconomic deprivation and rurality of 
patients reduces the accuracy with which one can esti-
mate the shape of their association with the outcome, 
with these factors likely to be important in terms of access 
to healthcare and prescribing. Third, not having informa-
tion about specific GP practice catchment areas made it 
necessary to use an adjacency matrix based on postcodes, 
rather than actual distances, resulting in a suboptimal 
method of accounting for underlying spatial processes. 
Fourth, we have not investigated how differences in GP 
prescribing practices for BOO may impact on the rates 
of surgical management of this condition. For example, 
a study in Australia identified regional differences in the 
surgical management of BOO secondary to BPH23; it 
would be interesting for future research to potentially link 
BPH prescribing practice with rates of surgical manage-
ment of this condition. For example, it might be the case 
that medical therapy can delay the need for surgery by 
a number of years, or reduced rates of BPH prescribing 
in any particular Health Board may be associated with 
higher rates of surgical intervention. These hypotheses 
require testing in data sets if they can be linked.
Further research to identify factors that lead to 
inequality in primary care practice is needed, and these 
is a need for data collection and data sharing to develop 
to enable this. It would also be interesting for future 
research to investigate trends and potential inequalities 
regarding all prostate- related conditions (both benign 
and malignant) over space and time in other settings and 
geographical locations. In particular, it would be inter-
esting to investigate whether the trends observed in Scot-
land may similarly exist in other regions of the UK, and if 
so, are variations attributable to common factors such as 
urban/rural and socioeconomic status. In addition, the 
general nature of the statistical modelling framework we 
have proposed in this study may be extended to investi-
gate other kinds of models, covariates and medical condi-
tions in a range of future studies.
CONCLUSIONS
The volume of prescriptions of drugs for LUTS secondary 
to BOO has steadily increased across Scotland during a 
recent 4- year observation period, consistent with trends 
in PCa, which similarly affects men of this age. Regional 
differences in the volume of prescribed drugs, and 
extremes in individual GP practice prescribing patterns, 
were found. While prescribing patterns varied in relation 
to geographic and demographic factors and GP practice 
list size, this study identified considerable variations that 
could not easily be accounted for. Potential explanations 
for these variations include individual GP attitudes and 
understanding of prostate diseases9 10 and Scotland’s 
cultural diversity.6–8
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Technical supplement for the paper “Prescribing patterns for medical 1 
treatment of suspected prostatic obstruction: a longitudinal register-based 2 
study the Scottish Health and Social Care Open Data” 3 
Authors: Federico Andreis, Richard Bryant, Emanuele Giorgi, Andrea Williamson, 4 
Ashleigh Ward 5 
 6 
We employ a Bayesian hierarchical Poisson model that estimates spatial and 7 
temporal structured patterns. The outcome of interest is the number of daily doses 8 
prescribed in a month at a general practice in Scotland, between October 2015 and 9 
November 2019. Let 𝑛𝑗𝑡𝑖 denote the number of prescriptions of drugs belonging to 10 
group 𝑗 ∈ {α − 1b, 5 − αri }, for practice 𝑖 = 1, … ,903, in month 𝑡 = 1, … ,50. 11 
Conditionally on a set of random effects α[𝑖], α[𝑗𝑖] and α[𝑡], let 𝑛𝑗𝑡𝑖 follow a Poisson 12 
distribution with parameter 𝜆𝑗𝑡𝑖, modelled with an additive linear predictor on a 13 
natural logarithm scale: 14 
𝑛𝑗𝑡𝑖~Poisson(𝜆𝑗𝑡𝑖) 15 log(𝜆𝑗𝑡𝑖) = 𝛼 + α[𝑖] + 𝛼[𝑗𝑖] + 𝛼[𝑡𝑗𝑖] + β1log(list size𝑡𝑖) + β2drug group + β3contract𝑖 +β4dispensing𝑖 + β5males 45p𝑡𝑖 + β6deprived 15𝑡𝑖 + β7remote𝑡𝑖  16 
The random effects, as described in Table 3 in the paper, relate to: 17 
- A structured component accounting for spatial correlation (α[𝑖]) 18 
- An unstructured component accounting for potential interactions between 19 
individual practice and type of drug (𝛼[𝑗𝑖]) 20 
- A component accounting for temporal correlation, grouped by health board 21 
and type of drug (α[𝑡]). 22 
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2 
 
To model the spatial component α[𝑖], we employ an intrinsic Conditional Auto 23 
Regressive (iCAR [1,2,3]) structure that exploits an adjacency matrix based on 24 
location of the practices. The postcodes are linked to Easting/Northing coordinates 25 
and Voronoi tessellation is used to find nearest neighbours and their distances (this 26 
was done using the caramellar package, available from github via 27 
devtools::install_github("barryrowlingson/caramellar")). In this way, the model allows 28 
the borrowing of strength of information across neighbouring regions. 29 
The component accounting for potential interactions between the individual medical 30 
practice and the type of drug prescribed 𝛼[𝑗𝑖] is modelled in an unstructured way, 31 
using iid gaussian terms with common precision parameter [3]. 32 
The temporal component α[𝑡] is modelled using a first-order autoregressive process 33 
[1], allowing grouping by health board and drug type. This approach allows the 34 
estimation of a common temporal autocorrelation structure for practices in the same 35 
health board and with respect to the same drug group type. 36 
An Integrated Nested Laplace Approximation [4] approach is used to approximate 37 
the posterior distribution and obtain the estimates, using the inla package in R; 38 
default prior distributions are used for all parameters. To make estimation 39 
computationally easier, a cheap Gaussian approximation is first used and the 40 
resulting estimates employed as reasonable starting values for the actual model 41 
fitting procedure (details in the R code in Supplement 2). Kullback-Leibler divergence 42 
statistics [3] indicate a satisfactory approximation to all marginal posterior densities. 43 
Figure 1 contains the summary of the model fit, while Table 1 contains a summary of 44 
estimated posterior distributions for the random effects in terms of standard 45 
deviations, rather than precision parameters (as in Figure 1). Estimation took 46 
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approximately 7 hours on an AMD Ryzen 7 2700x processor with 32GB DDR4 RAM, 47 
under Windows 10. 48 
Figure 1. Summary of model fit 49 
 50 
Table 1. Summary of estimated posterior distributions for random effects. SD denotes the standard 51 
deviation. 52 
 mean Sd 2.5% 50% 97.5% mode 
SD of 𝛼[𝑖] (spatial) 0.480 0.018 0.446 0.480 0.516 0.480 
SD of 𝛼[𝑗𝑖] (unstructured) 0.222 0.004 0.214 0.222 0.231 0.222 
SD of 𝛼[𝑡𝑗𝑖] (temporal) 0.188 0.019 0.157 0.185 0.231 0.178 𝜌1 of 𝛼[𝑡𝑗𝑖] (autocorrelation) 0.899 0.013 0.871 0.900 0.923 0.901 𝜌2 of 𝛼[𝑡𝑗𝑖] (group 
correlation) 
0.685 0.043 0.604 0.683 0.771 0.676 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open




[1] Banerjee S, Carlin BP, Gelfand AE. Hierarchical Modeling and Analysis for 54 
Spatial Data. 2nd ed. Boca Raton: Chapman & Hall. 2015. 55 
[2] Paciorek CJ. Understanding Intrinsic Gaussian Markov Random Field Spatial 56 
Models, Including Intrinsic Conditional Autoregressive Models. University of 57 
California, Berkeley. 2009. 58 
http://www.stat.berkeley.edu/~paciorek/research/techVignettes/techVignette5.pdf. 59 
[3] Rue H, Held L. Gaussian Markov Random Fields: Theory and Applications. Boca 60 
Raton: Chapman & Hall. 2005. 61 
[4] H. Rue, S. Martino, and N. Chopin. Approximate Bayesian inference for latent 62 
Gaussian models using integrated nested Laplace approximations (with discussion). 63 
Journal of the Royal Statistical Society, Series B. 2009; 71(2):319--392. 64 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-042606:e042606. 11 2021;BMJ Open, et al. Andreis F
####################################################################### 
# Code to reproduce the analyses and the plots in the the manuscript  # 
# "Prescribing patterns for medical treatment of suspected prostatic  # 
#  obstruction: a longitudinal register-based study the Scottish      # 
#  Health and Social Care Open Data" (2020)                           # 
# Authors: Federico Andreis, Richard Bryant, Emanuele Giorgi,         # 








# libraries # 
############# 
library(tidyverse)    # to manipulate data objects 
 
library(rgdal)        # to deal with spatial objects 
library(sf)            
library(raster)  
 
library(caramellar)   # to build the adjacency matrix, not on CRAN 
                      # 
devtools::install_github("barryrowlingson/caramellar") 
 
library(INLA)         # to fit the model 
library(brinla)       # to manipulate inla objects 
 
###################################### 
# load the dataset and the shapefile # 
###################################### 
dataset <- read_csv('dataset.csv') 
 
map_scotland_hb <- readOGR('SG_NHS_HealthBoards_2018.shp') 
 
########################### 
# create adjacency matrix # 
########################### 
 
# create adjacency matrix and transform it into an inla graph 
adjacency_graph <- voronoi_adjacency(dataset %>% 
                                       group_by(postcode_n) %>% 
                                       slice(1) %>% 
                                       
dplyr::select(postcode_n,Easting,Northing) %>% 
                                       ungroup, 
                                     
postcode_n~Easting+Northing)$Adjacencies %>% inla.read.graph 
 
################# 
# fit the model # 
################# 
 
# set inla controls 
control <-list(predictor=list(compute=TRUE,link=1),  
               results=list(return.marginals.random=TRUE,  
                            return.marginals.predictor=TRUE),  
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               compute=list(hyperpar=TRUE, return.marginals=TRUE,  
                            dic=TRUE, mlik=TRUE, cpo=TRUE, po=TRUE,  
                            waic=TRUE, graph=TRUE, gdensity=TRUE)) 
 
# model specification 
model <- n_daily_doses~drug_group+gp_run+dispensing+     # fixed effects 
                 log(list_size)+prop_m_45p+p_15+ur_code+ # fixed effects 
  f(postcode_n,model='besag',graph=adjacency_graph)+     # structured 
spatial component (iCAR) 
  f(time_n,model='ar1',group=hb_drug)+                   # temporal 
component (grouped AR1) 
  f(gp_drug,model='iid')                                 # unstructured 
spatial component (iid) 
 
# fit the model using a cheap Gaussian approximation to obtain reasonable 
starting values 
# run time ~18 minutes on a AMD Ryzen 7 2700x processor with 32GB DDR4 
RAM, under Windows 10 
cheap_approximation <- inla(model, 
                            family='poisson', 
                            data=dataset, 
                            control.inla=list(diagonal=100, 
                                              strategy="gaussian", 
                                              int.strategy="eb"), 
                            control.compute=control$compute, 
                            control.predictor=control$predictor, 
                            control.results=control$results, 
                            verbose=TRUE) 
 
# use the command 
# 
# model_fit <- cheap_approximation 
# 
# and ignore the following model fit block to be able to use the rest of 
the  
# code without having to wait for the more accurate approximation to be 
obtained 
# Note: if you use this approach, the resulting estimates and plots will 
differ 
# from those in the paper 
 
 
# fit the model using the cheap approximation estimates as starting 
values 
# note: this step takes ~7 hours on the machine described earlier 
model_fit <- inla(model, 
                  family='poisson', 
                  data=dataset, 
                  control.inla=list(diagonal=10), 
                  control.fixed = list(prec.intercept = 0.1), 
                  control.compute=control$compute, 
                  control.predictor=control$predictor, 
                  control.results=control$results, 
                  control.mode=list(result=cheap_approximation, 
                                    restart=TRUE), 
                  verbose=TRUE) 
 
rm(adjacency_graph,control, 
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   model,cheap_approximation) # clean up 
 
####################################### 
# post-processing of the model output # 
####################################### 
 
# add the fitted values to the dataset and make health board names into 
factors 
dataset <- dataset %>%  
  mutate(fitted=model_fit$summary.fitted.values$mean, 
         hb_name=factor(hb_name)) 
 
# obtain predictions by health board and drug group 
average_fitted <- dataset %>% 
  group_by(time=time,hb_name,drug_group) %>%  
  summarise(avg_fitted=mean(fitted), 
            avg_observed=mean(n_daily_doses)) 
 
# extract the exponentiated spatial residuals and add them to the dataset 
exp_residuals <- numeric(length(model_fit$marginals.random$postcode_n)) 
 
for (i in 1:length(exp_residuals)) { 
   
  tmp <- model_fit$marginals.random$postcode_n[[i]] 
   
  exp_residuals[i] <- inla.emarginal(exp,tmp) # exponentiate the spatial 
residuals 
   
} 
 
rm(tmp,i) # clean up 
 
# make the residuals  into a tibble that also contains the practice 
postcodes  
# and health boards names 
exp_residuals <- data.frame(postcode_n=1:length(exp_residuals), 
                            postcode=unique(dataset$postcode), 
                            exp_residuals=exp_residuals) %>% 
  mutate(postcode=as.character(postcode)) %>% 
  left_join(.,dataset %>% 
              dplyr::select(postcode,hb_name), 
            by=c('postcode','postcode')) %>%  
  group_by(postcode) %>%  
  slice(1) 
 
# add the exponentiated residuals to the dataset 
dataset <- left_join(dataset, 
                     exp_residuals %>%  
                       dplyr::select(postcode_n,exp_residuals), 
                     by='postcode_n') 
 
# set up the shapefile and data needed to to plot the map in Figure 3 
geo_df <- dataset 
coordinates(geo_df) <- ~Easting+Northing 
crop_map_hb <- crop(map_scotland_hb,geo_df) 
 
rm(map_scotland_hb) # clean up 
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# obtain the quantiles of the exponentiate residuals distribution 
# residuals are constant for each GP practice, extract only one line each 
dataset_singletons <- dataset %>%  
  group_by(gp_code) %>%  
  slice(1) %>%  
  ungroup 
 
exp_residuals_quantiles <- quantile(dataset_singletons$exp_residuals, 
                                    p=seq(0,1,by=.025)) 
 
################################## 
# produce the plots in the paper # 
################################## 
 
# Figure 1 
average_fitted %>% 
  ggplot(aes(x=time))+ 
  geom_line(aes(y=avg_fitted,linetype=drug_group))+ 
  theme_bw()+facet_wrap(~hb_name)+ 
  xlab('date')+ylab('number of daily doses per month (estimated)') 
 
# Figure 2 
exp_residuals %>%  
  group_by(hb_name) %>%  
  mutate(q1=quantile(exp_residuals,.25), 
         q2=quantile(exp_residuals,.5), 
         q3=quantile(exp_residuals,.75), 
         w=1.5*(q3-q1)) %>%  
  ungroup %>%  
  ggplot()+geom_histogram(aes(exp_residuals))+ 
  geom_vline(xintercept = 1, lty=2)+ 
  ylim(-3,18)+ 
  geom_hline(yintercept=0,col='grey')+ 
  geom_segment(aes(y=-2,yend=-2,x=q1-w,xend=q1))+ 
  geom_segment(aes(y=-2,yend=-2,x=q1,xend=q3),lwd=2)+ 
  geom_segment(aes(y=-2,yend=-2,x=q3,xend=q3+w))+ 
  geom_point(aes(y=-2,x=q2),lwd=2,pch=16,col='white')+ 
  geom_point(aes(y=-2,x=q2),lwd=2,pch=1)+ 
  theme_bw()+facet_wrap(~hb_name) 
 
# Figure 3 
 
# change quantiles as needed 
lower_quantile <- 2   # corresponding to 2.5% in the quantiles vector 
upper_quantile <- 40  # corresponding to 97.5% in the quantiles vector   
 
# create the proportions of GP practices meeting the quantile 
requirements 
prop_q_by_hb <- dataset_singletons %>%  
  group_by(hb_name) %>%  
  summarise(HBCode=first(hb_code), 
            prop_l_q2.5=mean(exp_res<quant_res[2]), 
            prop_g_q97.5=mean(exp_res>quant_res[40])) 
 
crop_map_hb@data <- crop_map_hb@data %>%  
  left_join(prop_q_by_hb,by='HBCode') 
 
# define a scaling factor for the grey scale: the max observed proportion 
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# is slightly less than 0.2, rescaling aids visualisation 




     main='high-volumes prescribers', 
     #border='black', 
     col=grey(1-crop_map_hb$prop_l_q2.5/scale_factor)) 
 
for (i in 0:5) { 
   
  rect(470000,750000+i*20000,520000,750000+(i+1)*20000, 
       col=grey(seq(1,0,length.out=6))[i+1]) 
  text(x=545000,y=760000+i*20000, 
       paste0(round(scale_factor*seq(0,1,length.out=6)[i+1]*100,2),' %'), 




     main='low-volumes prescribers', 
     #border='black', 
     col=grey(1-crop_map_hb$prop_g_q97.5/scale_factor)) 
 
for (i in 0:5) { 
   
  rect(470000,750000+i*20000,520000,750000+(i+1)*20000, 
       col=grey(seq(1,0,length.out=6))[i+1]) 
  text(x=545000,y=760000+i*20000, 
       paste0(round(scale_factor*seq(0,1,length.out=6)[i+1]*100,2),' %'), 





   lower_quantile,upper_quantile) # clean up 
 
################################### 
# posterior distributions summary # 
################################### 
 
# table of fixed effects posterior estimates 
model_fit$summary.fixed 
 
# table of random effects posterior estimates 
model_fit$summary.random        # expressed in terms of precision 
bri.hyperpar.summary(model_fit) # expressed in terms of standard 
deviation 
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